Inflammatory pseudotumor (IPT) is a rare tumor that occurs in various organs and tissues. The clinical picture varies from the more frequent benign lesions to the rare malignant tumors with distant metastases. IPT associated with hematopoietic stem cell transplantation (HSCT) is rarely reported. In this article, we review the reports of IPT after HSCT and describe the first case of bladder IPT. We also review the possible factors involved in the pathogenesis. IPT might be rare but it is a potentially serious complication of HSCT. It should be considered in patients with otherwise unexplained inflammatory symptoms or signs or with any mass lesion in the post-HSCT period. A knowledge of this entity and insistence on a definitive biopsy of mass lesions in the post-HSCT period can avoid unnecessary treatment such as radical surgery, chemotherapy or radiotherapy.
Introduction
Inflammatory pseudotumor (IPT) is a rare and usually benign tumor that is difficult to distinguish from malignant tumors by imaging techniques. It may be asymptomatic or it may present with inflammatory or mass-related symptoms and signs. 1 The pathogenesis is still unclear. IPT of different organs associated with hematopoietic stem cell transplantation (HSCT) has rarely been reported. [2] [3] [4] [5] We describe a 32-year-old man who developed bladder IPT after allogeneic HSCT, and review the reported cases. To our knowledge, this is the first bladder IPT to be reported after HSCT.
Case report
A 32-year-old male was diagnosed with acute myeloblastic leukemia (AML)-M5 in March 2001. He underwent allogeneic HSCT in April 2002 in the first remission. His past history was only significant for a smoking habit of 15 pack-years. Conditioning was with busulfan 4 mg/kg/day, orally on days À7 to À4, and cyclophosphamide (CY) 60 mg/kg/day, i.v. on days À3 and À2. In order to prevent CY-induced hemorrhagic cystitis (HC), he received hyperhydration and mesna (30 mg/kg, four times a day) during CY infusion. He experienced dysuria with macroscopic hematuria and clots in the urine on day À1. Urinary system ultrasonography on day þ 14 revealed an increase in bladder wall thickness and a dense echogenic lesion with irregular contours. This was thought to be a clot. On day þ 17, he underwent cystoscopy under general anesthesia and a mass of clot was found in the bladder. After this had been removed, there was no active bleeding. The gross appearance was consistent with HC. The hemorrhagic fields were cauterized and he was catheterized for bladder irrigation. With irrigation, the urine color became lighter and the catheter was removed on day þ 36. Meanwhile, leukocyte and thrombocyte engraftment occurred on days þ 20 and þ 26, respectively. He had not developed any major complications apart from infections (neutropenic fever treated with cefepime and isepamicin; nosocomial pneumonia treated with imipenem and amikacin; possible catheter infection treated with vancomycin). However, during follow-up, his urine became blood-red in color with clots, necessitating erythrocyte transfusion. Urinary system ultrasound on day þ 71 revealed a mobile echogenic mass in the bladder. The mass was accepted as a clot since it was mobile. He was again catheterized for irrigation. Upon disappearance of the macroscopic hematuria, his irrigation catheter was removed on day þ 84. However, ultrasonography on day þ 90 demonstrated a fixed mass. He underwent a second cystoscopy on day þ 99. This time, the gross appearance of the lesion was consistent with a typical solid bladder tumor, 2.5 Â 1 cm in size. Complete transurethral resection (TUR) of the mass was performed. However, pathologic examination revealed nodular lesions consisting of fusiform cells, infiltrating the lamina propria and muscularis propria. The mesenchymal cells were atypical, pleomorphic and were forming bundles ( Figures  1 and 2) . Immunohistochemical examination revealed immunoreactivity with vimentin and actin but not with S-100. Cytokeratin was patchily positive. The Ki 67 proliferation index was less than 5% in the mesenchymal cells. He was thus diagnosed as having IPT of the bladder. The tumor recurred twice as seen at cystoscopies performed 2 months apart. Recurrences were smaller than the initial lesion (1.5 and 0.5 cm, respectively). They were also treated by TUR. He is now completely healthy with no further recurrences or major transplant-related complications 5 years after transplantation.
Discussion
IPT following HSCT is very rare in the literature and has been reported in only five patients to date. [2] [3] [4] [5] Patient characteristics are given in Table 1 .
Fangusaro et al. 2 reported the first cases of IPT after HSCT in two pediatric patients. The first case was an 8-year-old boy with acute lymphocytic leukemia (ALL) who achieved remission after second-line chemotherapy. Following conditioning with high-dose cytosine arabinoside and total body irradiation (TBI), he underwent allogeneic HSCT. Major early complications were acute skin and gut graft versus host disease (GVHD). Liver IPT appeared at 28 months, presenting with abdominal distention. The patient underwent right hepatic lobectomy with complete resection of the mass. He remained in good clinical condition 7 months postoperatively, with no recurrence. The second case was a 3-year-old male with neuroblastoma. Following conditioning with carboplatin, etoposide, melphalan and TBI, he received an autologous HSCT. He first developed an esophageal stricture due to radiation therapy after 2 years and underwent balloon dilatation. At follow-up esophagogram 4 months later, a filling defect was noted within the esophagus. He remained asymptomatic. After surgical resection, the mass was diagnosed as IPT. He again remained well with no difficulty in swallowing and no recurrence. The third case was a 23-year-old female who underwent allogeneic HSCT for ALL. 3 She developed IPT of the kidney after 10 months, presenting with anemia and low-grade fever. Unilateral nephrectomy was performed, after which the fever resolved and the anemia improved. The fourth case was a 50-yearold female who had undergone allogeneic HSCT for AML. Conditioning was with 120 mg/kg CY and TBI. Her course was significant only for chronic GVHD before IPT. She developed brain IPT at approximately 19 months, 4 presenting with sensory disturbance involving the left side of the body. Tumor resection was performed and wholebrain radiotherapy was given before the histological diagnosis was available. She died of fungal infection 5 months after IPT had been diagnosed. Case 5 was a 42-year-old male who underwent allogeneic HSCT for AML. 5 Conditioning was with 16 mg/kg busulfan and 120 mg/kg CY. He developed extensive chronic GVHD, with involvement of gut, liver and oral mucosa. Following invasive pulmonary aspergillosis, he developed lung IPT at 12 months, presenting with dyspnea. High-dose steroid treatment provided resolution of both pulmonary and GVHD symptoms. Our patient constitutes the sixth patient to be reported with IPT after HSCT.
Currently, IPT is generally accepted as a true neoplasm with a wide spectrum of biological behavior. The clinical picture varies from the more frequent benign lesions to the rare tumors, which are multifocal and prone to recurrence. 6 Local and vascular invasions are common. IPT may rarely undergo malignant transformation occasionally with distant metastases. 7, 8 This is why Coffin et al. emphasized its neoplastic nature and proposed the use of 'inflammatory myofibroblastic tumor' term rather than 'inflammatory pseudotumor'. 1, 7 Although the lung is the best-known and Inflammatory pseudotumor after HSCT G Bahat et al most common site for involvement, the lesion may occur in diverse extrapulmonary locations. In their report of the largest IPT series to date, Coffin et al. described 84 patients. Constitutional symptoms and signs of an inflammatory process including fever, weight loss and pain, together with mass and site-specific symptoms, were the presenting complaints. 1 Laboratory abnormalities included anemia, thrombocytosis, polyclonal hypergammaglobulinemia and elevated erythrocyte sedimentation rate. The sites of involvement were mostly abdomen, retroperitoneum and pelvis, followed by head, neck, upper respiratory tract, trunk and extremities. However, the pathogenesis and relationship to HSCT is still unclear and many factors are implicated.
Infection has been already conjectured as a factor for IPT development. Hepatitis C virus, EBV, HIV, bacterial, fungal and mycobacterial infections have been reported to precede IPT. 1, 7 These are mostly IPT-related organ-specific infections, and concurrent infection is usually not documented. 6 Among IPTs developing after HSCT, there was a preceding pulmonary infection before lung IPT in patient 5. However, our patient did not experience any infection related to the bladder.
The other factor suggested as related to IPT is a 'reactive' process. 7 This may result from an unusual response to noninfectious agents such as trauma or surgery. There are also reports of pancreas IPT in a smoker with a heavy alcohol consumption, 9 of bladder IPT in patients with misplaced sutures or chronic cystitis who have undergone frequent instrumentation, [10] [11] [12] and small bowel, axilla and neck IPTs in patients with surgical gauze retention. 13 Among the IPT cases in the post-HSCT period, in patient 2, the esophageal IPT developed after balloon dilatation of the stricture. Our patient developed IPT after severe HC and frequent instrumentation. These observations also suggested a reactive process in response to a noninfectious agent.
Chemotherapy and radiotherapy are also potential predisposing factors. 1, 7, [14] [15] [16] [17] [18] [19] Use of CY is specifically mentioned as associated with bladder IPT in a recently published report. 10 All of the patients with IPT after HSCT were given high-dose chemotherapy and some also received TBI. We consider that chemotherapy, particularly CY when associated with subsequent HC, may have been a contributing factor for IPT in our patient.
For IPTs developing after HSCT, immunosuppression and GVHD are the two factors most likely to be associated. 2, 5 Recovery of immune function after HSCT takes as long as 5 years after allogeneic 20 and 2 years after autologous HSCT. 21 Thus, immunosuppression may be a contributing factor. With GVHD, chronic stimulation of the cellular immune system might be the principal factor. Among patients developing IPT after HSCT, two of six (patients 4 and 5) were reported to have chronic GVHD. However, in our patient, there were no symptoms or signs related to GVHD. On the other hand, the clinical courses in patients who developed IPT after HSCT were not significantly atypical for such patients and a genetic predisposition can therefore not be excluded.
In our patient, we also suggest smoking as a contributing factor. Smoking is associated with pancreas and bladder Inflammatory pseudotumor after HSCT G Bahat et al IPT, 9, 10 and is a well-known factor predisposing to the development of upper aerodigestive tract and bladder neoplasms. Since IPT is a neoplastic process, we propose that smoking might be a predisposing factor.
Although IPT is a rare tumor, it can have significant impact on patient morbidity after HSCT. It generally has a much better prognosis than a carcinoma, however. Increased morbidity may derive from its location in a vital organ or from treatment given owing to misdiagnosis as cancer. 1, 10 It is difficult to distinguish IPT from malignant tumors by imaging techniques, and timing of the lesion may give a very important clue. IPT occurs earlier in the posttransplant period ranging between 3 months and 2.5 years after SCT, whereas the secondary malignancies due to irradiation and anticancer agents occur as later transplant complications, diagnosed at a median of 4.6 years. 22 Definitive histological evaluation of the mass should always be undertaken to avoid unnecessary treatment-related complications.
In summary, we conclude that IPT developing in different organs can be a rare, but potentially serious, complication of HSCT. It should be considered in patients with otherwise unexplained inflammatory symptoms/signs or any mass lesion in the post-HSCT period. Definitive histologic evidence is essential in its diagnosis and differentiation from other tumors.
